ArticleWorld journal of orthopedics2017
Glucosamine and chondroitin for the treatment of osteoarthritis.
Article in World journal of orthopedics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review.Nutrients · 2025Pooled it
- Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- Feasibility & Efficacy of Deprescribing rounds in a Singapore rehabilitative hospital- a randomised controlled trial.BMC geriatrics · 2021Trial
- Nutraceuticals, Social Interaction, and Psychophysiological Influence on Pet Health and Well-Being: Focus on Dogs and Cats.Veterinary sciences · 2025Review
- Complementary, alternative, and integrative medicine therapies for knee osteoarthritis: a visual analytics analysis of the research domain.Frontiers in medicine · 2025Article
- Nanoparticles as Drug Delivery Vehicles for People with Cystic Fibrosis.Biomimetics (Basel, Switzerland) · 2024Review
- Acid-resistant enzymes: the acquisition strategies and applications.Applied microbiology and biotechnology · 2023Review
- Chondroitin sulfate and glucosamine combination in patients with knee and hip osteoarthritis: A long-term observational study in Russia.World journal of orthopedics · 2023Article
- Article
- Heterologous production of chondroitin.Biotechnology reports (Amsterdam, Netherlands) · 2022Review
- The promising role of autologous and allogeneic mesenchymal stromal cells in managing knee osteoarthritis. What is beyond Mesenchymal stromal cells?Journal of clinical orthopaedics and trauma · 2022Review
- Association between glucosamine use and cancer mortality: A large prospective cohort study.Frontiers in nutrition · 2022Article
- Pain management in hemophilia: expert recommendations.Wiener klinische Wochenschrift · 2021Review
- The impact of pharmaceutical care on the efficacy and safety of transdermal glucosamine sulfate and capsaicin for joint pain.International journal of clinical pharmacy · 2021Article
- Undenatured Type II Collagen Ameliorates Inflammatory Responses and Articular Cartilage Damage in the Rat Model of Osteoarthritis.Frontiers in veterinary science · 2021Article
- Nonsurgical Management of Cartilage Defects of the Knee: Who, When, Why, and How?The journal of knee surgery · 2020Review
- Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Untargeted metabolite profiling on the water-soluble metabolites of edible bird's nest through liquid chromatography-mass spectrometry.Veterinary world · 2020Article
- Reduction of osteoarthritis severity in the temporomandibular joint of rabbits treated with chondroitin sulfate and glucosamine.PloS one · 2020Article
- Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management.Pharmaceutical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of primary or idiopathic osteoarthritis (OA) of knee and hip joints has substantially increased in general population during the last decades. Analgesics and non-steroidal anti-inflammatory drugs are currently extensively used as non-surgical treatment options. However, they act as symptomatic treatments, not offering a cure of OA and they are accused for an increased risk of adverse events. Glucosamine (GL) and chondroitin (CH) are nutritional supplements that have recently gained widespread use as treatment options for OA. They potentially or theoretically act as chondroprotectors or/and as "disease-modifying OA drugs" offering not only symptomatic relief but also alteration of the natural history of OA. However, although many studies have showed a significant treatment effect, accompanied with remarkable safety, there is still controversy regarding their relative effectiveness compared with placebo or other treatments. The scope of this review is to present and critically evaluate the current evidence-based information regarding the administration of GL and CH for the treatment of knee or hip OA. Our focus is to investigate the clinical efficacy and safety after the use of these supplements. An effect of GL and CH on both clinical and radiological findings has been shown. However, only a few high-quality level I trials exist in the literature, especially on the assessment of radiological progression of OA. The effect sizes are generally small and probably not clinically relevant. Even the validity of these results is limited by the high risk of bias introduced in the studies. Both GL and CH seem to be safe with no serious adverse events reported. There is currently no convincing information for the efficacy of GL and CH on OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.